119006-58-5

Upstream product

• 874501-48-1 2-hydroxy-4-propyl-benzoic acid ethyl ester 
• 620971-18-8 1-(methoxymethoxy)-3-propylbenzene 
• 621-27-2 3-n-propylphenol 

Downstream Products

• 621-27-2 3-n-propylphenol 
• 891859-11-3 (2-methoxy-4-propylphenyl)methanol 
• 891859-41-9 6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydro-2-naphthalenecarbaldehyde 
• 891859-12-4 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic acid 

Relevant academic research and scientific papers

Discovery of a 1-Methyl-3,4-dihydronaphthalene-Based Sphingosine-1-Phosphate (S1P) Receptor Agonist Ceralifimod (ONO-4641). A S1P1 and S1P5 Selective Agonist for the Treatment of Autoimmune Diseases

The discovery of 1-({6-[(2-methoxy-4-propylbenzyl)oxy]-1-methyl-3,4-dihydronaphthalen-2-yl}methyl)azetidine-3-carboxylic acid 13n (ceralifimod, ONO-4641), a sphingosine-1-phosphate (S1P) receptor agonist selective for S1P1 and S1P5, is described. While it has been revealed that the modulation of the S1P1 receptor is an effective way to treat autoimmune diseases such as relapsing-remitting multiple sclerosis (RRMS), it was also reported that activation of the S1P3 receptor is implicated in some undesirable effects. We carried out a structure-activity relationship (SAR) study of hit compound 6 with an amino acid moiety in the hydrophilic head region. Following identification of a lead compound with a dihydronaphthalene central core by inducing conformational constraint, optimization of the lipophilic tail region led to the discovery of 13n as a clinical candidate that exhibited >30 000-fold selectivity for S1P1 over S1P3 and was potent in a peripheral lymphocyte lowering (PLL) test in mice (ED50 = 0.029 mg/kg, 24 h after oral dosing).

External preparation for skin

An external preparing for skin comprising one or more than two types of 2-hydroxy benzoic acid derivative and/or salt thereof represented by the following formula: STR1 wherein R is an alkoxy group or alkyl group in the formula. The external preparation for the skin according to the present invention has a suppression effect on melanine generation by inhibition of tyrosinase activity. Accordingly, an excellent bleaching effect based upon the suppression of chromatosis and a high degree of safety can be obtained.